# Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

> **NCT00603356** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** OSI-930 and erlotinib

## Key facts

- **NCT ID:** NCT00603356
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2010-04
- **Final completion:** 2010-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2011-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00603356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00603356, "Phase I Study of OSI-930 and Erlotinib in Cancer Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00603356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*